Dr. Emile Loria has more than 25 years of experience in the pharmaceutical and biotechnology sectors, occupying key positions, in particular with Ciba-Geigy and Sanofi Pharma. He was a researcher at the Cancer Institute in Villejuif and then at the Cancer and Immunogenetics Institute (INSERM-CNRS) founded by professor Georges Mathé. In 1986, he founded MS Medical Synergy, a drug management company. He then joined Biovector Therapeutics where he became Chairman and Chief Executive Officer.
In 2001, Dr. Loria was appointed Chief Executive Officer of Epimmune and developed the epitopes technology, from which the Tedopi® epitopes stem. He ran this programme from initial research to the start of the Phase 2 clinical trial. In 2012, he purchased, via OPI sa (Geneva), all of the Memopi® assets, co-founded OSE Pharma and became Chairman of its Board.
Dr. Loria is a doctor who specialises in oncology.
Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at FRAMATOME (Areva). Over a 20 year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. Ms Hiance also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.
Ms. Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.
In 2008, Ms. Hiance co-founded and served as Chairman of the Board of Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology.
Vice Chairman of the Board of OSE Immunotherapeutics, Ms Hiance also serves as Strategy Advisor to the company’s Management.
Ms. Hiance holds an Engineering Degree from the « Ecole Polytechnique Feminine », Paris, and a Nuclear Engineering Degree from the « Institut des Sciences et Techniques », Grenoble.
With more than 20 years of experience in the pharmaceutical industry, Dr. Dominique Costantini has overseen many therapeutic innovations in the international framework of oncology. Throughout her career, she held a number of management positions within HMR (now Sanofi) where she led medico-marketing activities to commercialize products (notably in immunology, endocrinology, infectious illnesses and oncology). While there, Ms. Costantini also participated in the development of various medicines, from conception to product approval and commercialization.
In 1997, Ms.Costantini founded BioAlliance Pharma, where she held the position of Chief Executive Officer until 2011 and during which time, she led BioAlliance Pharma’s IPO on Euronext (2005). BioAlliance Pharma originated Livatag®, an anti-cancer nanotechnology in primary liver cancer, currently in Phase 3 (in Europe and the USA). In her experience, Ms. Costantini has been the source of many international industrial partnerships (Europe, USA, China, Japan and Korea). To date, BioAlliance Pharma (renamed Onxeo in 2014) is the only French biotechnology company to have two FDA drug approvals.
In 2012, Ms. Costantini co-founded and led OSE Pharma as Chief Executive Officer.
Dr. Dominique Costantini is a doctor (Paris V university), who specialises in immunology.
Immunologist, Doctor in Veterinary Science and Transplant specialist, Sophie Brouard has completed her postdoctoral degree at the Harvard Medical School in Boston. Director of Research at the « Institut National de la Santé et Recherche Médicale » (INSERM, National Institute for Health and Medical Research) in Nantes, she is in charge of a research unit dedicated to transplantation and its mechanism. Dr. Brouard is currently involved in understanding transplant rejection mechanisms in order to identify biomarkers of graft survival.
In parallel, Dr. Brouard serves as Director of the CentaureE Foundation, a renowned foundation and pioneer in pancreas transplant. Thanks to a strong commitment of its research and surgical teams, this foundation performs around two-thirds of simultaneous kidney-pancreas transplants in France.
Centaure is also known worlwide for its research on immunological mechanisms of diabetes in experimental models, and in the conduct of clinical trials in diabetic patients. Centaure federates 3 French centres of excellence – Nantes, Lyon and Paris – working together on research in transplantation, in connection with a European and U.S. international committee.
In 2004, Dr. Brouard received the Bronze medal from the french CNRS national research institute. She was a co-founder of Effimune and is the author of more than 130 peer-reviewed scientific publications, and currently holds 10 patents.
Guy Chatelain is a lawyer practising in Geneva, associated with the firm Mentha & Associés. He is a specialist in company law (tax law, contract law) and is also a member of the Genevan Business Law Association and the Swiss Arbitration Association.
Jean-Patrick Demonsang served as President and Managing Director of Seventure Partners (Paris based private equity fund) until 2013. During his career, he has supported the activities of more than 150 companies invoved in the information technology and life sciences sectors. Mr. Demonsang is also an entrepreneur who has participated in the creation of a number of small- and medium-sized businesses. He is also at the root of the first club for start-ups.
Mr. Demonsang holds a MBA from the French business school HEC and a physics degree.
Brigitte Dréno, M.D., Ph.D., is head of the Department of Dermatology at the Nantes University Hospital, a department with significant expertise in research and innovative treatments in skin oncology. She is the director of the Biotherapy Clinical Investigation Centre, director of the Unit of Cell and Gene Therapy and vice dean for Research Medical Faculty. Within her operational functions and research responsibilities,
Dr. Dréno is very much involved in immuno-oncology innovation. In collaboration with the academic leadership, she supports the implementation of OSE Immunotherapeutics’ R&D initiatives on the Nantes’ University campus.
Walter Flamenbaum brings more than 40 years of experience in the medical sector. An internist, nephrologist and pharmacologist, during his career he has also served as a medical professor at Mount Sinaï Hospital in New York and the Tufts medical school in Boston. A founding member of the private equity firm Paul Capital Healthcare Funds, Mr. Flammenbaum is an expert in issues related to intellectual property rights in the context of obtaining licences for medicine and medical devices, as well as identifying investment opportunities in the healthcare sector. Mr. Flamenbaum is also a strategy manager and adviser to numerous healthcare companies.
Didier Hoch is a physician and has been working in the pharmaceutical and vaccine industries for 25 years. From 2000 to 2010, Dr. Hoch was Chairman of Sanofi Pasteur MSD (European JV for vaccines between Sanofi Aventis & Merck), a leader in the European vaccines market and was involved in the launch of Gardasil. Previously, he was in charge of various functions within Rhône Poulenc Rorer (then Aventis) for Europe and Middle East Africa, including commercial, marketing and general management. Prior to that, Dr.Hoch served as President (2003-09), and Vice President (2002 & 2010) of the « European Vaccine Manufacturers Association » (EVM).
He is currently President of the Life Science Health Committee of the MEDEF (French Global industry association) and President of Biotechnology Committee of the LEEM (French Pharma industry association).
Diane Kathryn Jorkasky, M.D., has over 20 years of pharmaceutical and biotechnology experience in medical and scientific leadership positions with industry-leading companies, including Endo Pharmaceuticals, Pfizer and GSK. She has extensive knowledge of and experience in all phases of drug research and development. Since 2012, Dr. Jorkasky has been executive vice president, chief medical officer, and head of development of Complexa Therapeutics, a biotechnology company specializing in treatments for inflammatory and fibrosis related diseases.
Alexis Peyroles has more than 15 years of management and financial control experience, having served in related positions, internationally. Alexis Peyroles joined Sanofi-Aventis in 1996, working first as Financial Controller in Japan before becoming Head of financial control for the Baltic states. He was subsequently named Head of activities for Business Development in Eastern Europe. In 2005, he joined the Guerbet group (a leader in the field of contrast products, especially in medical imaging) as Financial Control Manager and in 2009, became Chief Executive Officer for Latin America, based in Brazil.
As soon as 2013, Alexis Peyroles has been involved in OSE Pharma and served as Chief Financial Officer and was in charge of Business Development. Upon the merger of OSE Pharma with Effimune in May 2016, he was appointed Chief Operating Officer of OSE Immunotherapeutics, in charge of Finance, Business Development and Operations.
Alexis Peyroles graduated from EDHEC Business School and holds an Imperial Executive MBA.
Gérard Tobelem is a former haematology professor at Paris 7 University and former Head of the department of blood disorders at the Lariboisière hospital in Paris, as well as past Executive Chairman of the French Blood Establishment. Mr. Tobelem’s research work was recognized when, in 2006, he was awarded the first Diderot Innovation prize. Mr Tobelem has practised strategic functions within the French Ministry of Higher Education and Research and has also advised different international pharmaceutical companies in their research and development strategies. Mr. Tobelem currently serves as non-executive Chairman of the Board of Directors of Theradiag.
David de Weese has 14 years of operational management experience in Europe and the USA. Mr. De Weese previously held the position of Chief Executive Officer of Machine Intelligence, a software company established in Silicon Valley, and he was the founder, Chairman and Chief Executive Officer of biotechnology companies New York-based – SigA Pharmaceuticals – and California-based – Cygnus Therapeutic Systems). He also founded medical device company, Medical Innovations. Mr. De Weese is currently the company director of the private equity fund Paul Capital, which he joined in 1995.